BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24496086)

  • 21. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
    Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
    Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder: A Randomized, Double-Blind, Controlled Trial.
    Hanling SR; Hickey A; Lesnik I; Hackworth RJ; Stedje-Larsen E; Drastal CA; McLay RN
    Reg Anesth Pain Med; 2016; 41(4):494-500. PubMed ID: 27187898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasound-guided stellate ganglion block for the treatment of migraine in elderly patients: A retrospective and observational study.
    Yu B; Hou S; Xing Y; Jia Z; Luo F
    Headache; 2023 Jun; 63(6):763-770. PubMed ID: 37314033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of stellate ganglion block on breast cancer-related lymphedema: comparison of various injectates.
    Park JH; Min YS; Chun SM; Seo KS
    Pain Physician; 2015; 18(1):93-9. PubMed ID: 25675063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).
    Ruan X; Bai W; Ren M; Kim T; Lee JY; Chuang FC; Wang PH; He W; Ma X; Miyazaki K; Song N; Wang X; Yu Q
    J Int Med Res; 2024 May; 52(5):3000605241247684. PubMed ID: 38818888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
    Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
    Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
    Rahman UA; Kashif TB; Usman M; Rana M; Hasanain M; Anjum MU; Cheema HA; Jaffar H; Bhattarai P
    Medicine (Baltimore); 2023 Dec; 102(50):e36592. PubMed ID: 38115258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
    Constantine GD; Simon JA; Kaunitz AM; Pickar JH; Revicki DA; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Nov; 27(11):1236-1241. PubMed ID: 33110039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrasound imaging for stellate ganglion block: direct visualization of puncture site and local anesthetic spread. A pilot study.
    Kapral S; Krafft P; Gosch M; Fleischmann D; Weinstabl C
    Reg Anesth; 1995; 20(4):323-8. PubMed ID: 7577781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of exercise for menopausal symptoms: a randomized controlled trial.
    Sternfeld B; Guthrie KA; Ensrud KE; LaCroix AZ; Larson JC; Dunn AL; Anderson GL; Seguin RA; Carpenter JS; Newton KM; Reed SD; Freeman EW; Cohen LS; Joffe H; Roberts M; Caan BJ
    Menopause; 2014 Apr; 21(4):330-8. PubMed ID: 23899828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.
    Cohen LS; Joffe H; Guthrie KA; Ensrud KE; Freeman M; Carpenter JS; Learman LA; Newton KM; Reed SD; Manson JE; Sternfeld B; Caan B; Freeman EW; LaCroix AZ; Tinker LF; Booth-Laforce C; Larson JC; Anderson GL
    Menopause; 2014 Apr; 21(4):347-54. PubMed ID: 23982113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Lung Function and Clinical Features of the Ultrasound-Guided Stellate Ganglion Block With 2 Different Concentrations of a Local Anesthetic: A Randomized Controlled Trial.
    Kim WJ; Park HS; Yi MS; Koo GH; Shin HY
    Anesth Analg; 2017 Apr; 124(4):1311-1316. PubMed ID: 28319552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials.
    Birkhaeuser M; Bitzer J; Braat S; Ramos Y
    Climacteric; 2019 Jun; 22(3):312-322. PubMed ID: 30712391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stellate-ganglion block: a new treatment for hot flushes?
    Loprinzi CL; Barton DL; Carns PE
    Lancet Oncol; 2008 Jun; 9(6):506-7. PubMed ID: 18510982
    [No Abstract]   [Full Text] [Related]  

  • 35. Stellate ganglion block attenuates chronic stress induced depression in rats.
    Wang W; Shi W; Qian H; Deng X; Wang T; Li W
    PLoS One; 2017; 12(8):e0183995. PubMed ID: 28859148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of stellate ganglion block on sedation as assessed by bispectral index in normal healthy volunteers.
    Yeo J; Jeon Y
    Pain Physician; 2015; 18(2):173-8. PubMed ID: 25794203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness, safety, and predictors of response to ultrasound-guided stellate ganglion blockades for the treatment of patients with chronic migraine: A retrospective and observational study.
    Yu B; Zhang W; Zhao C; Xing Y; Meng L; Luo F
    Pain Pract; 2023 Jul; 23(6):609-617. PubMed ID: 36929196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
    Johnson KA; Martin N; Nappi RE; Neal-Perry G; Shapiro M; Stute P; Thurston RC; Wolfman W; English M; Franklin C; Lee M; Santoro N
    J Clin Endocrinol Metab; 2023 Jul; 108(8):1981-1997. PubMed ID: 36734148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
    Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
    Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity.
    Whiteley J; Wagner JS; Bushmakin A; Kopenhafer L; Dibonaventura M; Racketa J
    Menopause; 2013 May; 20(5):518-24. PubMed ID: 23403500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.